Principles and Consequences of Enzyme Induction
Enzyme induction represents an increase in activity and accelerated synthesis of microsomal enzymes caused by exogenous inducers (typically lipophilic substances that act as substrates for these enzymes themselves). The process affects both phase I (non-synthetic reactions) and phase II biotransformation (predominantly glucuronide conjugation).
The main clinical consequence of induction is the accelerated breakdown of drugs. This leads to a drop in their blood concentrations and a weakening or complete loss of therapeutic effect. A classic example is the decreased reliability of oral contraceptives (estrogens) when co-administered with classic inducers, creating a risk of unintended pregnancy.
The development of the effect directly depends on the drug and takes time:
- Slow type: The classic inducer Phenobarbitalum takes weeks to exert its full effect because the organism requires time to synthesize new protein molecules.
- Fast type: Rifampicinum increases enzyme activity within just 2 to 4 days after initiation.
Risks of Induction: Autoinduction, Toxification, and Carcinogenesis
Induction does not always mean a simple decrease in drug efficacy. In several situations, it poses a direct threat to the patient's health:
- Toxification. If toxic compounds are formed during metabolism, their accelerated synthesis increases the risk of complications. For example, combining paracetamol with CYP2E1 inducers (chronic ethanol consumption or the antitubercular drug Isoniazidum) dramatically increases the risk of liver injury due to the accumulation of hepatotoxic metabolites.
- Autoinduction. A phenomenon where a drug accelerates its own metabolism. The substance stimulates the production of enzymes that degrade it. Long-term use of barbiturates (phenobarbital) causes tolerantia, weakening their pharmacological action.
- Carcinogenesis. Certain dietary and environmental components become carcinogens only after metabolic activation. The drug Omeprazolum, by inducing CYP1A1 and CYP1A2 isoforms, can increase the risk of forming active carcinogens.
Mechanisms and Dangers of Inhibition
During inhibition, a drug suppresses the activity of cytochrome P-450 enzymes. This slows down the metabolism of other drugs utilizing the same pathway. Their plasma concentrations steadily rise, leading to the risk of toxic effects (effectus toxici). Unlike induction, inhibition does not require the synthesis of new proteins and develops rapidly—effects are observed within 24 hours.
Clinically significant interactions:
- Warfarin (anticoagulant): Its oxidation via CYP3A4/3A5 is inhibited by cimetidine, macrolides, ketoconazole, or ciprofloxacin. The result is an excessive enhancement of the anticoagulant effect and risk of hemorrhage (haemorrhagia).
- Cyclosporine (immunosuppressant): Antifungal azoles slow its breakdown, critically increasing nephrotoxicity (nephrotoxicitas).
- Theophylline: The antibiotic ciprofloxacin blocks the CYP1A2 isoform, causing a sharp rise in theophylline toxicity.
The Prodrug Paradox
A special scenario occurs with prodrugs—substances that are converted into their active metabolites only during biotransformation.
In this case, enzyme inhibition blocks drug activation, which paradoxically leads to a decrease in therapeutic effect. A striking clinical example is the co-administration of the antiplatelet drug clopidogrel and omeprazole. The antiulcer agent blocks the CYP2C19 isoform (the main activation pathway for clopidogrel). As a result, the concentration of the active metabolite drops, and the patient's risk of thrombosis increases.
Impact of Diet, Herbal Products, and Transport Proteins
Pharmacokinetics is actively altered by diet, herbal remedies, and environmental factors:
- Herbal inducers: St. John's wort (Hypericum perforatum) induces CYP3A4, weakening the efficacy of concomitant medications.
- Dietary inhibitors: Furanocoumarins in grapefruit juice potently block CYP3A4 directly in the intestinal wall, increasing the oral bioavailability of many drugs and the risk of toxicity.
- Environmental factors: Polycyclic aromatic hydrocarbons from tobacco smoke and industrial pollutants (dioxins, polychlorinated biphenyls) act as potent inducers of microsomal oxidation in smokers and industrial workers.
Additionally, metabolic inducers and inhibitors frequently affect transport proteins, particularly P-glycoprotein (P-glycoproteinum). This efflux transporter alters drug absorption and distribution. St. John's wort induces it, whereas grapefruit juice inhibits it.
Clinical strategy: Whenever an inducer or inhibitor is added or withdrawn, mandatory dosage adjustments of the primary medication are required to prevent toxicity or loss of efficacy.